<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TYLENOL WITH CODEINE - acetaminophen and codeine phosphate tablet </strong><br>PD-Rx Pharmaceuticals, Inc.<br></p></div>
<h1>TYLENOL<span class="Sup">®</span><br> with Codeine<br> CIII<br> (acetaminophen and codeine phosphate) tablets</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-1"></a><p></p>
<h1><span class="Emphasis">HEPATOTOXICITY</span></h1>
<p class="First"><span class="Bold">Acetaminophen has been associated with cases of <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">acute liver failure</span>, at times resulting in liver transplant and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Most of the cases of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product (see <a href="#war">WARNINGS</a>).</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">TYLENOL<span class="Sup">®</span> with Codeine is supplied in tablet form for oral administration. 						</p>
<p>Acetaminophen, 4'-hydroxyacetanilide, a slightly bitter, white, odorless, crystalline powder, is a  						non-opiate, non-salicylate analgesic and antipyretic.  It has the following structural formula:</p>
<div class="Figure">
<img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=96847717-e3ff-42ee-a25b-1df72c427572&amp;name=codeine-01.jpg"><p class="MultiMediaCaption">C<span class="Sub">8</span> H<span class="Sub">9</span>  						NO<span class="Sub">2</span>       M.W. 151.16</p>
</div>
<p>Codeine phosphate, 7,8-didehydro-4,  						5α-epoxy-3-methoxy-17-methylmorphinan-6α-ol phosphate (1:1) (salt) hemihydrate, a white  						crystalline powder, is a narcotic analgesic and antitussive. It has the following structural formula:</p>
<div class="Figure">
<img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=96847717-e3ff-42ee-a25b-1df72c427572&amp;name=codeine-02.jpg"><p class="MultiMediaCaption">C<span class="Sub">18</span>H<span class="Sub">21</span>NO<span class="Sub">3</span>•H<span class="Sub">3</span>PO<span class="Sub">4</span>•1/2 H<span class="Sub">2</span>O       M.W. 406.37</p>
</div>
<p>Each tablet contains:</p>
<a name="ie49b4617-9d5d-4abf-824a-505b5c268605"></a><table width="50%">
<col align="left" valign="top" width="50%">
<col align="right" valign="top" width="50%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left">Acetaminophen</td>
<td align="right">300 mg</td>
</tr>
<tr>
<td align="left">No. 3 Codeine Phosphate</td>
<td align="right">30 mg</td>
</tr>
<tr><td align="center" colspan="2">(Warning: May be habit forming) </td></tr>
<tr>
<td align="left"> </td>
<td align="right"></td>
</tr>
<tr>
<td align="left">Acetaminophen</td>
<td align="right">300 mg</td>
</tr>
<tr>
<td align="left">No. 4 Codeine Phosphate</td>
<td align="right">60 mg</td>
</tr>
<tr class="Botrule Last"><td align="center" colspan="2">(Warning: May be habit forming) </td></tr>
</tbody>
</table>
<p>In addition, each tablet contains the following inactive ingredients:</p>
<p>TYLENOL<span class="Sup">®</span> with Codeine No. 3 contains powdered cellulose, magnesium stearate, sodium metabisulfite<a name="footnote-reference-1" href="#footnote-1" class="Sup">1</a>, pregelatinized starch (corn), and modified starch (corn).</p>
<p>TYLENOL<span class="Sup">®</span> with Codeine No. 4 contains powdered cellulose, magnesium stearate, sodium metabisulfite<a href="#footnote-1" class="Sup">1</a>, pregelatinized starch (corn), and corn starch.</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">1</a></dt>
<dd>See<a href="#war"> WARNINGS</a>
</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">This product combines the <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effects</span> of a centrally acting analgesic, codeine, with a peripherally acting analgesic, acetaminophen.</p>
<div class="Section" data-sectionCode="43682-4">
<a name="section-2.1"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">The behavior of the individual components is described below.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.1"></a><p></p>
<h3>Codeine</h3>
<p class="First">Codeine is rapidly absorbed from the gastrointestinal tract. It is rapidly distributed from the intravascular spaces to the various body tissues, with preferential uptake by parenchymatous organs such as the liver, spleen, and kidney. Codeine crosses the blood-brain barrier and is found in fetal tissue and breast milk. The plasma concentration does not correlate with brain concentration or relief of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>; however, codeine is not bound to plasma proteins and does not accumulate in body tissues.</p>
<p>The plasma half-life is about 2.9 hours. The elimination of codeine is primarily via the kidneys, and about 90% of an oral dose is excreted by the kidneys within 24 hours of dosing. The urinary secretion products consist of free and glucuronide conjugated codeine (about 70%), free and conjugated norcodeine (about 10%), free and conjugated morphine (about 10%), normorphine (4%), and hydrocodone (1%). The remainder of the dose is excreted in the feces.</p>
<p>At therapeutic doses, the <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span> reaches a peak within 2 hours and persists between 4 and 6 hours.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.2"></a><p></p>
<h3>Acetaminophen</h3>
<p class="First">Acetaminophen is rapidly absorbed from the gastrointestinal tract and is distributed throughout most body tissues. The plasma half-life is 1.25 to 3 hours, but may be increased by <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver damage</span> and following overdosage. Elimination of acetaminophen is principally by liver metabolism (conjugation) and subsequent renal excretion of metabolites. Approximately 85% of an oral dose appears in the urine within 24 hours of administration, most as the glucuronide conjugate, with small amounts of other conjugates and unchanged drug.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">TYLENOL<span class="Sup">®</span> with Codeine (acetaminophen and codeine phosphate) Tablets are indicated for the relief of mild to moderately severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">This product should not be administered to patients who have previously exhibited <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to codeine or acetaminophen.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="war"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1"></a><p></p>
<h2>Hepatotoxicity</h2>
<p class="First"><span class="Bold">Acetaminophen has been associated with cases of <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">acute liver failure</span>, at times resulting in liver transplant and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Most of the cases of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product. The excessive intake of acetaminophen may be intentional to cause self-harm or unintentional as patients attempt to obtain more <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief or unknowingly take other acetaminophen-containing products (see <a href="#BOX">Boxed Warning</a>).</span></p>
<p><span class="Bold">The risk of <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">acute liver failure</span> is higher in individuals with underlying liver disease and in individuals who ingest alcohol while taking acetaminophen.</span></p>
<p><span class="Bold">Instruct patients to look for acetaminophen or APAP on package labels and not to use more than one product that contains acetaminophen. Instruct patients to seek medical attention immediately upon ingestion of more than 4,000 milligrams of acetaminophen per day, even if they feel well.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>/<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span></h2>
<p class="First">There have been post-marketing reports of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> associated with the use of acetaminophen. Clinical signs included <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, mouth, and throat, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. There were infrequent reports of life-threatening <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> requiring emergency medical attention. Instruct patients to discontinue TYLENOL<span class="Sup">®</span> with Codeine immediately and seek medical care if they experience these symptoms. Do not prescribe TYLENOL<span class="Sup">®</span> with Codeine for patients with acetaminophen <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.3"></a><p></p>
<h2>Head Injuries</h2>
<p class="First">In the presence of <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span> or other intracranial lesions, the respiratory-depressant effects of codeine and other narcotics may be markedly enhanced, as well as their capacity for elevating cerebrospinal fluid pressure. Narcotics also produce other CNS-depressant effects, such as <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, that may further obscure the clinical course of the patients with head injuries.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.4"></a><p></p>
<h2>Acute Abdominal Conditions</h2>
<p class="First">Codeine or other narcotics may obscure signs on which to judge the diagnosis or clinical course of patients with acute abdominal conditions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.5"></a><p></p>
<h2>Abuse Potential</h2>
<p class="First">Codeine is habit forming and potentially abusable. Consequently, the extended use of this product is not recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.6"></a><p></p>
<h2>Sulfite Sensitivity</h2>
<p class="First">TYLENOL<span class="Sup">®</span> with Codeine (acetaminophen and codeine phosphate) Tablets contain sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> than in nonasthmatic people.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">TYLENOL<span class="Sup">®</span> with Codeine (acetaminophen and codeine phosphate) Tablets should be prescribed with caution in certain special-risk patients, such as the elderly or debilitated, and those with severe impairment of renal or hepatic function, head injuries, elevated intracranial pressure, acute abdominal conditions, <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, <span class="product-label-link" type="condition" conceptid="195590" conceptname="Urethral stricture">urethral stricture</span>, Addison's disease, or <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="urmoc"></a><a name="section-6.1.1"></a><p></p>
<h3>Ultra-Rapid Metabolizers of Codeine</h3>
<p class="First">Some individuals may be ultra-rapid metabolizers due to a specific CYP2D6*2×2 genotype. These individuals convert codeine into its active metabolite, morphine, more rapidly and completely than other people. This rapid conversion results in higher than expected serum morphine levels. Even at labeled dosage regimens, individuals who are ultra-rapid metabolizers may experience <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> symptoms such as extreme <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, or <span class="product-label-link" type="condition" conceptid="4302536" conceptname="Shallow breathing">shallow breathing</span>.</p>
<p>The prevalence of this CYP2D6 phenotype varies widely and has been estimated at 0.5% to 1% in Chinese and Japanese, 0.5% to 1% in Hispanics, 1% to 10% in Caucasians, 3% in African Americans, and 16% to 28% in North Africans, Ethiopians, and Arabs. Data are not available for other ethnic groups.</p>
<p>When physicians prescribe codeine-containing drugs, they should choose the lowest effective dose for the shortest period of time and inform their patients about these risks and the signs of morphine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> (see<span class="Bold"><a href="#nursing"> PRECAUTIONS – Nursing Mothers</a></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-6.2"></a><p></p>
<h2>Information for Patients/Caregivers</h2>
<ul>
<li>Do not take TYLENOL<span class="Sup">®</span> with Codeine if you are allergic to any of its ingredients.</li>
<li>If you develop signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> such as a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>, stop taking TYLENOL<span class="Sup">®</span> with Codeine and contact your healthcare provider immediately.</li>
<li>Do not take more than 4,000 milligrams of acetaminophen per day. Call your healthcare provider if you took more than the recommended dose.</li>
<li>Codeine may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery. Avoid such tasks while taking this product.</li>
<li>Alcohol and other CNS depressants may produce an additive <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span> when taken with this combination product. Avoid drinking alcohol or taking other CNS depressants when you are taking Tylenol with Codeine.</li>
<li>Codeine may be habit forming. Take this drug only for as long as it is prescribed, in the amounts prescribed, and no more frequently than prescribed.</li>
<li>Some people have a variation in a liver enzyme and change codeine into morphine more rapidly and completely than other people. These people are ultra-rapid metabolizers and are more likely to have higher-than-normal levels of morphine in their blood after taking codeine, which can result in <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> symptoms such as extreme <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, or <span class="product-label-link" type="condition" conceptid="4302536" conceptname="Shallow breathing">shallow breathing</span>. In most cases, it is unknown if someone is an ultra-rapid codeine metabolizer.</li>
<li>Nursing mothers taking codeine can also have higher morphine levels in their breast milk if they are ultra-rapid metabolizers. These higher levels of morphine in breast milk may lead to life-threatening or fatal side effects in nursing babies. If you are a nursing mother, watch for signs of morphine toxicity in your infant, including increased <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> (more than usual), difficulty breastfeeding, breathing difficulties, or limpness. Talk to your baby's doctor immediately if you notice these signs. If you cannot reach the doctor right away, take your baby to an emergency room or call 911 (or local emergency services).</li>
</ul>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="section-6.3"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">In patients with severe hepatic or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, effects of therapy should be monitored with serial liver and/or renal function tests.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-6.4"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">This drug may enhance the effects of other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="section-6.5"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First">Codeine may increase serum amylase levels.</p>
<p>Acetaminophen may produce false-positive test results for urinary 5-hydroxyindoleacetic acid.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-6.6"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No adequate studies have been conducted in animals to determine whether acetaminophen and codeine have a potential for carcinogenesis or mutagenesis. No adequate studies have been conducted in animals to determine whether acetaminophen has a potential for impairment of fertility.</p>
<p>Acetaminophen and codeine have been found to have no mutagenic potential using the Ames <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span>-Microsomal Activation test, the Basc test on Drosophila germ cells, and the Micronucleus test on mouse bone marrow.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-6.7"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-6.7.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.7.1.1"></a><p></p>
<h4>Pregnancy Category C</h4>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.7.1.1.1"></a><p></p>
<h5>Codeine</h5>
<p class="First">A study in rats and rabbits reported no teratogenic effect of codeine administered during the period of organogenesis in doses ranging from 5 to 120 mg/kg. In the rat, doses at the 120 mg/kg level, in the toxic range for the adult animal, were associated with an increase in embryo resorption at the time of implantation. In another study a single 100 mg/kg dose of codeine administered to pregnant mice reportedly resulted in delayed ossification in the offspring.</p>
<p>There are no adequate and well-controlled studies in pregnant women. TYLENOL<span class="Sup">® </span>with Codeine (acetaminophen and codeine phosphate) Tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="section-6.7.2"></a><p></p>
<h3>Nonteratogenic Effects</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span> has been reported in newborns whose mothers took opiates regularly during pregnancy. Withdrawal signs include <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, excessive <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. These signs usually appear during the first few days of life.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="section-6.8"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">Narcotic analgesics cross the placental barrier. The closer to delivery and the larger the dose used, the greater the possibility of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in the newborn. Narcotic analgesics should be avoided during labor if delivery of a premature infant is anticipated. If the mother has received narcotic analgesics during labor, newborn infants should be observed closely for signs of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. Resuscitation may be required (see<a href="#overdosage"> OVERDOSAGE</a>). The effect of codeine, if any, on the later growth, development, and functional maturation of the child is unknown.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="nursing"></a><a name="section-6.9"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Acetaminophen is excreted in breast milk in small amounts, but the significance of its effect on nursing infants is not known. Because of the potential for serious adverse reactions in nursing infants from acetaminophen, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</p>
<p>Codeine is secreted into human milk. In women with normal codeine metabolism (normal CYP2D6 activity), the amount of codeine secreted into human milk is low and dose-dependent. Despite the common use of codeine products to manage postpartum <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, reports of adverse events in infants are rare. However, some women are ultra-rapid metabolizers of codeine. These women achieve higher-than-expected serum levels of codeine's active metabolite, morphine, leading to higher-than-expected levels of morphine in breast milk and potentially dangerously high serum morphine levels in their breastfed infants. Therefore, maternal use of codeine can potentially lead to serious adverse reactions, including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, in nursing infants.</p>
<p>The prevalence of this CYP2D6 phenotype varies widely and has been estimated at 0.5% to 1% in Chinese and Japanese, 0.5% to 1% in Hispanics, 1% to 10% in Caucasians, 3% in African Americans, and 16% to 28% in North Africans, Ethiopians, and Arabs. Data are not available for other ethnic groups.</p>
<p>The risk of infant exposure to codeine and morphine through breast milk should be weighed against the benefits of breastfeeding for both the mother and baby. Caution should be exercised when codeine is administered to a nursing woman. If a codeine-containing product is selected, the lowest dose should be prescribed for the shortest period of time to achieve the desired clinical effect. Mothers using codeine should be informed about when to seek immediate medical care and how to identify the signs and symptoms of neonatal toxicity, such as <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> or sedation, difficulty breastfeeding, breathing difficulties, and decreased tone, in their baby. Nursing mothers who are ultra-rapid metabolizers may also experience <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> symptoms such as extreme <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, or <span class="product-label-link" type="condition" conceptid="4302536" conceptname="Shallow breathing">shallow breathing</span>. Prescribers should closely monitor mother-infant pairs and notify treating pediatricians about the use of codeine during breastfeeding (see<span class="Bold"><a href="#urmoc"> PRECAUTIONS – General, Ultra-Rapid Metabolizers of Codeine</a></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The most frequently observed adverse reactions include <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, sedation, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. These effects seem to be more prominent in ambulatory than in nonambulatory patients, and some of these adverse reactions may be alleviated if the patient lies down.</p>
<p>Other adverse reactions include <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="4148767" conceptname="Dysphoric mood">dysphoria</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>.</p>
<p>At higher doses, codeine has most of the disadvantages of morphine including <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>.</p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="section-8"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="34085-1">
<a name="section-8.1"></a><p></p>
<h2>Controlled Substance</h2>
<p class="First">TYLENOL<span class="Sup">®</span> with Codeine (acetaminophen and codeine phosphate) Tablets are classified as a Schedule III controlled substance.</p>
</div>
<div class="Section" data-sectionCode="34086-9">
<a name="section-8.2"></a><p></p>
<h2>Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></h2>
<div class="Section" data-sectionCode="34087-7">
<a name="section-8.2.1"></a><p></p>
<p class="First">Codeine can produce <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug dependence</span> of the morphine type and, therefore, has the potential for being abused. Psychological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, and tolerance may develop upon repeated administration and it should be prescribed and administered with the same degree of caution appropriate to the use of other oral narcotic medications.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="overdosage"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Following an acute overdosage, toxicity may result from codeine or acetaminophen.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2>Signs and Symptoms</h2>
<p class="First">Toxicity from <span class="Bold Italics">codeine</span> <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> includes the opioid triad of pinpoint pupils, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of respiration, and <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> may occur.</p>
<p>In <span class="Bold Italics">acetaminophen</span> overdosage, dose-dependent, potentially fatal <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span> is the most serious adverse effect. <span class="product-label-link" type="condition" conceptid="444044" conceptname="Acute tubular necrosis">Renal tubular necrosis</span>, <span class="product-label-link" type="condition" conceptid="380688" conceptname="Hypoglycemic coma">hypoglycemic coma</span>, and coagulation defects may also occur.</p>
<p>Early symptoms following a potentially hepatotoxic <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> may include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, and <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">general malaise</span>. Clinical and laboratory evidence of hepatic toxicity may not be apparent until 48 to 72 hours post-ingestion.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<h2>Treatment</h2>
<p class="First">A single or <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">multiple drug overdose</span> with acetaminophen and codeine is a potentially lethal polydrug <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> and consultation with a regional poison control center is recommended.</p>
<p>Immediate treatment includes support of cardiorespiratory function and measures to reduce drug absorption.</p>
<p>Oxygen, intravenous fluids, vasopressors, and other supportive measures should be employed as indicated. Assisted or controlled ventilation should also be considered. For <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> due to overdosage or unusual sensitivity to codeine, parenteral naloxone is a specific and effective antagonist.</p>
<p>Gastric decontamination with activated charcoal should be administered just prior to N-acetylcysteine (NAC) to decrease systemic absorption if acetaminophen ingestion is known or suspected to have occurred within a few hours of presentation.  Serum acetaminophen levels should be obtained immediately if the patient presents 4 or more hours after ingestion to assess potential risk of hepatotoxicity; acetaminophen levels drawn less than 4 hours post-ingestion may be misleading. To obtain the best possible outcome, NAC should be administered as soon as possible where impending or evolving <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> is suspected. Intravenous NAC may be administered when circumstances preclude oral administration.</p>
<p>Vigorous supportive therapy is required in severe <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>. Procedures to limit the continuing absorption of the drug must be readily performed since the hepatic injury is dose-dependent and occurs early in the course of <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Dosage should be adjusted according to severity of  <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and response of the patient.</p>
<p>The usual adult dosage is:</p>
<a name="if94d7c7f-a2d1-45f1-85c4-af6d6aa26741"></a><table width="100%">
<col align="left" valign="top" width="33%">
<col align="center" valign="top" width="33%">
<col align="center" valign="top" width="34%">
<thead><tr class="First Last">
<th align="left"></th>
<th align="center">Single Doses (Range)</th>
<th align="center">Maximum 24-Hour Dose</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Toprule" align="left">Codeine Phosphate</td>
<td align="center">15 mg to 60 mg</td>
<td align="center">360 mg</td>
</tr>
<tr class="Last">
<td align="left">Acetaminophen</td>
<td align="center">300 mg to 1,000 mg</td>
<td align="center">4,000 mg</td>
</tr>
</tbody>
</table>
<p>Doses may be repeated up to every 4 hours.</p>
<p>The prescriber must determine the number of tablets per dose, and the maximum number of tablets per 24 hours, based upon the above dosage guidance. This information should be conveyed in the prescription.</p>
<p>It should be kept in mind, however, that tolerance to codeine can develop with continued use and that the incidence of untoward effects is dose related. Adult doses of codeine higher than 60 mg fail to give commensurate relief of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> but merely prolong <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> and are associated with an appreciably increased incidence of undesirable side effects.  Equivalently high doses in children would have similar effects.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">TYLENOL<span class="Sup">®</span> with Codeine (acetaminophen and codeine phosphate) Tablets are white, round, flat-faced, beveled-edged tablet, imprinted "McNEIL" on one side and "TYLENOL CODEINE" and either "3" or "4" on the other side and are supplied as follows:</p>
<p>TYLENOL<span class="Sup">®</span> with Codeine No. 3 bottle of 100 tablets – NDC 50458-513-60</p>
<p>TYLENOL<span class="Sup">®</span> with Codeine No. 3 bottle of 1000 tablets – NDC 50458-513-80 </p>
<p>TYLENOL<span class="Sup">®</span> with Codeine No. 4 bottle of 100 tablets – NDC 50458-515-60</p>
<p>TYLENOL<span class="Sup">®</span> with Codeine No. 4 bottle of 500 tablets – NDC 50458-515-70 </p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-11.1"></a><p></p>
<p class="First">Store TYLENOL<span class="Sup">®</span> with Codeine Tablets at 20° to 25°C (68° to 77°F). (See USP Controlled Room Temperature.)</p>
<p>Dispense in tight, light-resistant container as defined in the official compendium.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<p class="First">Manufactured by:<br>Janssen Ortho, LLC<br>Gurabo, Puerto Rico 00778</p>
<p>Manufactured for:<br>PriCara<span class="Sup">®</span><br>Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.<br>Raritan, New Jersey 08869</p>
<p>10186601</p>
<p>Revised September 2011</p>
<p>© Ortho-McNeil-Janssen Pharmaceuticals, Inc. 2000</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 100 Tablet Bottle Label</h1>
<p class="First"><span class="Bold"><br></span></p>
<p><span class="Bold">CIII</span></p>
<p>100 tablets</p>
<p><span class="Bold">Tylenol</span><span class="Sup">®</span><br><span class="Bold">with codeine</span><br>ACETAMINOPHEN AND<br>CODEINE PHOSPHATE<br>TABLETS<span class="Bold"> No.3</span></p>
<p>Each tablet contains:<br>codeine phosphate 30 mg<br>acetaminophen 300 mg</p>
<p><span class="Bold">Rx only.</span></p>
<div class="Figure"><img alt="55289048 Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=96847717-e3ff-42ee-a25b-1df72c427572&amp;name=55289048.jpg"></div>
<br>PDRx Label<br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TYLENOL WITH CODEINE 		
					</strong><br><span class="contentTableReg">acetaminophen and codeine phosphate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55289-048(NDC:50458-513)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>acetaminophen</strong> (acetaminophen) </td>
<td class="formItem">acetaminophen</td>
<td class="formItem">300 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>codeine phosphate</strong> (codeine anhydrous) </td>
<td class="formItem">codeine phosphate</td>
<td class="formItem">30 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>powdered cellulose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium metabisulfite</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>starch, corn</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">McNEIL;TYLENOL;CODEINE;3</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55289-048-15</td>
<td class="formItem">15  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA085055</td>
<td class="formItem">08/17/1977</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>PD-Rx Pharmaceuticals, Inc.
							(156893695)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>PD-Rx Pharmaceuticals, Inc. (156893695)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">PD-Rx Pharmaceuticals, Inc.</td>
<td class="formItem"></td>
<td class="formItem">156893695</td>
<td class="formItem">repack(55289-048)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 7/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>eea44671-f761-4b46-aea0-975ee6d4acaa</div>
<div>Set id: 96847717-e3ff-42ee-a25b-1df72c427572</div>
<div>Version: 3</div>
<div>Effective Time: 20110726</div>
</div>
</div> <div class="DistributorName">PD-Rx Pharmaceuticals, Inc.</div></p>
</body></html>
